Effect of Iron Therapy on Platelet Counts in Patients with Inflammatory Bowel Disease-Associated Anemia
Open accessThe DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND AIMS: Secondary thrombocytosis is a clinical feature of unknown significance. In inflammatory bowel disease (IBD), thrombocytosis is considered a marker of active disease; however, iron deficiency itself may trigger platelet generation. In this study we tested the effect of iron therapy on platelet counts in patients with IBD-associated anemia. METHODS: Platelet counts were analyzed before and after iron therapy from four prospective clinical trials. Further, changes in hemoglobin, transferrin saturation, ferritin, C-reactive protein, and leukocyte counts, before and after iron therapy were compared. In a subgroup the effect of erythropoietin treatment was tested. The results were confirmed in a large independent cohort (FERGIcor). RESULTS: A total of 308 patient records were available for the initial analysis. A dose-depended drop in platelet counts (mean 425 G/L to 320 G/L; p<0.001) was found regardless of the type of iron preparation (iron sulphate, iron sucrose, or ferric carboxymaltose). Concomitant erythropoietin therapy as well as parameters of inflammation (leukocyte counts, C-reactive protein) had no effect on the change in platelet counts. This effect of iron therapy on platelets was confirmed in the FERGIcor study cohort (n=448, mean platelet counts before iron therapy: 383 G/L, after: 310 G/L, p<0.001). CONCLUSION: Iron therapy normalizes elevated platelet counts in patients with IBD-associated anemia. Thus, iron deficiency is an important pathogenetic mechanism of secondary thrombocytosis in IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As detailed elsewhere in this special issue, both absolute ID and inflammation can also result in thrombocytosis due to the effects of altered thrombopoietin, EPO, and IL-6 levels on megakaryopoiesis [105–107].”
From Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation (2016) · cites this paper as [106]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Iron, anaemia, and inflammatory bowel diseases
Gasche, C., Lomer, M. C. E., Cavill, I., & Weiss, G. (2004) · Gut · doi:10.1136/gut.2003.035758 · Cited by 494 · cited 1×
“IBD-associated anemia is caused by a combination of anemia of chronic disease and iron deficiency [10].”
BackgroundGasche, C., Berstad, A., Befrits, R., Beglinger, C., Dignass, A., Erichsen, K., Gomollon, F., Hjortswang, H., Koutroubakis, I., Kulnigg, S., et al. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20285 · Cited by 450 · cited 1×
“Accordingly, guidelines recommend iron replacement in combination with anti-inflammatory drugs and/or erythropoietin [11,12].”
BackgroundEvstatiev, R., Marteau, P., Iqbal, T., Khalif, I. L., Stein, J., Bokemeyer, B., Chopey, I. V., Gutzwiller, F. S., Riopel, L., & Gasche, C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.005 · Cited by 367 · cited 2×
“To confirm these unexpected findings we also analyzed a recent independent cohort of patients (from FERGIcor; [16]).”
MethodResultSelf-citationKulnigg, S., Stoinov, S., Simanenkov, V., Dudar, L. V., Karnafel, W., Garcia, L. C., Sambuelli, A. M., D'Haens, G., & Gasche, C. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01744.x · Cited by 349 · cited 1×
“In the ‘‘Ferric carboxymaltose study’’ [49], 200 patients with anemia and IBD were randomized 2:1 to ferric carboxymaltose (total median amount 1400 mg iron, n = 137) or oral iron sulphate (200 mg/day, n = 63).”
BackgroundSystematic review: managing anaemia in Crohn's disease
KULNIGG, S., & GASCHE, C. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03146.x · Cited by 325 · cited 1×
“About one third of patients with inflammatory bowel disease (IBD) suffer from anemia [6–9].”
BackgroundDiagnosis and management of iron deficiency anemia in patients with IBD
Stein, J., Hartmann, F., & Dignass, A. U. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.151 · Cited by 304 · cited 1×
“About one third of patients with inflammatory bowel disease (IBD) suffer from anemia [6–9].”
BackgroundPlatelets Kill Intraerythrocytic Malarial Parasites and Mediate Survival to Infection
McMorran, B. J., Marshall, V. M., de Graaf, C., Drysdale, K. E., Shabbar, M., Smyth, G. K., Corbin, J. E., Alexander, W. S., & Foote, S. J. (2009) · Science · doi:10.1126/science.1166296 · Cited by 291
Platelets in Inflammatory Bowel Disease: Clinical, Pathogenic, and Therapeutic Implications
Danese, S., Motte, C. D. L., & Fiocchi, C. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04129.x · Cited by 253 · cited 1×
“Some authors propose that activated platelets are involved in the pathogenesis of IBD [14,15].”
BackgroundSIMANEK, R., VORMITTAG, R., AY, C., ALGUEL, G., DUNKLER, D., SCHWARZINGER, I., STEGER, G., JAEGER, U., ZIELINSKI, C., & PABINGER, I. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03680.x · Cited by 249 · cited 1×
“In cancer patients thrombocytosis is an independent risk factor for thromboembolic events [45].”
BackgroundAnemia and inflammatory bowel diseases
Gomollón, F., & Gisbert, J. P. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.4659 · Cited by 194 · cited 1×
“About one third of patients with inflammatory bowel disease (IBD) suffer from anemia [6–9].”
Background
Research works printed but not linked: 1
- C Gasche, 2011, [Diagnosis and treatment of iron deficiency and anaemia in inflammatory bowel diseases. Consensus of the Austrian IBD Working Party]., Z Gastroenterol, 49, 627
Cited by
‘Fit to fly’: overcoming barriers to preoperative haemoglobin optimization in surgical patients
Muñoz, M., Gómez-Ramírez, S., Kozek-Langeneker, S., Shander, A., Richards, T., Pavía, J., Kehlet, H., Acheson, A. G., Evans, C., Raobaikady, R., et al. (2015) · British Journal of Anaesthesia · doi:10.1093/bja/aev165 · Cited by 238
“enhances the response to rHuEPO allowing dose reduction and reduction of platelet counts diminishing thrombotic risk.(66) 20 | Muñoz et al.”
BackgroundWallaert, J. B., De Martino, R. R., Marsicovetere, P. S., Goodney, P. P., Finlayson, S. R. G., Murray, J. J., & Holubar, S. D. (2012) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e3182698f60 · Cited by 149
“A recent study demonstrated that iron therapy in patients with IBD-associated anemia normalizes thrombocytosis, thus decreasing the risk of thrombosis.(15) In our VTE subgroup, 62% of patients had a preoperative hematocrit <37%, whereas only 2% had recently received a transfusion.”
BackgroundNairz, M., Theurl, I., Wolf, D., & Weiss, G. (2016) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-016-0505-7 · Cited by 152
Iron deficiency alters megakaryopoiesis and platelet phenotype independent of thrombopoietin
Evstatiev, R., Bukaty, A., Jimenez, K., Kulnigg‐Dabsch, S., Surman, L., Schmid, W., Eferl, R., Lippert, K., Scheiber‐Mojdehkar, B., Michael Kvasnicka, H., et al. (2014) · American Journal of Hematology · doi:10.1002/ajh.23682 · Cited by 124
“In addition, ID-induced thrombocytosis resolves upon iron replacement even in patients receiving erythropoiesis stimulating agents [3,4,30].”
BackgroundResultSelf-citationFerric Carboxymaltose: A Review of Its Use in Iron Deficiency
Keating, G. M. (2014) · Drugs · doi:10.1007/s40265-014-0332-3 · Cited by 138
“2) suggests that iron deficiency may be an important mechanism underlying secondary thrombocytosis [17, 18].”
Background
Metadata
- Authors
- Kulnigg-Dabsch, S., Evstatiev, R., Dejaco, C., & Gasche, C.
- Affiliations
- Medical University of Vienna (AT)
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-04-10
- Volume
- 7
- Issue
- 4
- Pages
- e34520
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3323537
- OpenAlex
- W2100551670
- Cited by
- 55
- References
- 52
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 4 · 2022: 5 · 2021: 4 · 2020: 2 · 2018: 4 · 2017: 2 · 2016: 6 · 2015: 9 · 2014: 9 · 2013: 4 · 2012: 1
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fresenius Medical Care North America
- Austrian Science Fund (P 21200)
- Vifor Pharma
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Keywords
- inflammatory bowel disease, iron deficiency, secondary thrombocytosis, platelet count, iron therapy, iron supplementation, erythropoietin, anemia of chronic disease, iron sucrose, ferric carboxymaltose, iron sulfate, transferrin saturation, ferritin, C-reactive protein
- MeSH terms
- Iron Deficiencies, Blood Platelets, C-Reactive Protein, Erythropoietin, Ferritins, Hemoglobins, Humans, Iron, Leukocyte Count, Platelet Count, Prospective Studies, Thrombocytosis, Transferrin, Inflammatory Bowel Diseases, Cohort Studies, Anemia, Iron-Deficiency, Iron Compounds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Iron Therapy on Platelet Counts in Patients with Inflammatory Bowel Disease-Associated Anemia. https://app.cochat.ai/papers/10.1371/journal.pone.0034520
- The paper
- Kulnigg-Dabsch, S., Evstatiev, R., Dejaco, C., & Gasche, C. (2012). Effect of Iron Therapy on Platelet Counts in Patients with Inflammatory Bowel Disease-Associated Anemia. PLoS ONE. https://doi.org/10.1371/journal.pone.0034520
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.